Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing.

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their success in managing blood sugar levels and drastically reducing weight. Between new clinical trial results and a boom in celebrity usage,

New research suggests GLP-1 medications like Ozempic may help reduce several health risks in addition to treating type 2 diabetes and obesity.